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Exercise Science

Effects of a yeast ß-glucan supplement on symptoms of upper respiratory tract infections
Chairperson: Brent Ruby, Ph.D.
The focus of previous research has demonstrated that both oat and yeast ß-glucan
benefits immunosuppressed populations. However, previous research has not, to our
knowledge, investigated the effects of a yeast ß-glucan on the ummune functioning of
healthy, free-living human populations. PURPOSE: The goal of this research was to
evaluate the effects of a yeast ß-glucan on symptoms of upper respiratory tract infection
in healthy, free-living, college-aged males. METHODOLOGY: The WURSS-44, a
reliable, validated survey used for determining symptoms of upper respiratory tract
infection was filled out online daily by 79 male subjects between the ages of 18 and 40.
Subjects were given a bottle of 250 mg capsules of either yeast ß-glucan or placebo to
take daily. RESULTS: Yeast ß-glucan demonstrated no statistically significant effect
on the experimental subject population for any of the variables associated with symptoms
of upper respiratory tract infection. CONCLUSION: Yeast ß-glucan does not
significantly improve immune functioning in healthy, free-living college aged males.
Keywords: ß-glucan, immune, susceptibility, resistance
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Chapter One: Introduction

Introduction

The immune system is a complex composition of cells and biological processes
that acts to protect the body from foreign pathogens and emergent tumor cells. The
human body is an ideal host for bacteria, fungi, and viruses, and there is a constant battle
between the evolving pathogens and the adaptation of the organism’s immune system to
protect the body. There are a number of pathogens that frequently escape the immune
system’s first defenses, which can affect other systems. Perhaps the most common area
affected by the incidence of immune system failure to detect and eliminate a threat is the
upper tract of the respiratory system. The result is often what we call an upper
respiratory tract infection (URTI), or the “common cold”. Research done in 2002
revealed that the average cold resulted in approximately 8.7 hours of work lost (Bramley
et al., 2002). Adults average 2-3 colds per year, which result in more than 45 million
days of work lost in the United States alone (Barrett et al., 2007; Bramley et al. 2002).
Lost productivity due to the common cold is estimated at over $25 billion per year
(Bramley et al. 2002). Research has been hard-pressed for decades to develop a clear
understanding of the common cold, let alone a cure or successful treatment.
There are a number of behaviors that have negative effects on the immune system
including the lack of exercise (Pederson and Hoffman-Goetz, 2000), excessive amounts
of exercise (Davis et al., 1997; Ceddia and Woods, 1999; Pederson and Hoffman-Goetz,
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2000; Nieman, 2000; Nieman, 2003), poor nutrition habits (Beisel, 1996), lack of sleep
(Dinges et al., 1995), and psychological stress (Wonnacott and Bonneau, 2002; KiecoltGlaser, 1999). College-aged students generally suffer any combination of these
behaviors, which may cause them to suffer physiologically and academically as a result
of getting an URTI (Tsai and Li, 2004).
Since it is necessary to find methods of preventing URTI in humans, research has
been directed to examine the effects of different supplements on immune function. Over
the past two decades, researchers have assessed the different affects of the carbohydrate
ß-glucan on the immune system. ß-glucan is a complex carbohydrate polymer found in
the cell walls of plants. It has been shown to lower cholesterol in humans (Jenkins et al.,
2002), promote antitumor activity in both humans and mice (Vetvicka et al., 1996), and
improve immune function in immunosuppressed populations of humans and mice (Yun et
al., 2003; Brown and Gordon, 2003; Brown and Gordon, 2005). The mode of ingestion
for mice and humans is generally oral; however, some human research uses muscular
injection. There is some debate among current research as to whether or not ß-glucan can
assist the immune system in preventing URTI (Nieman et al., 2008). These debates
generally arise because ß-glucan may have the most benefit in subjects who are clinically
diagnosed as immunosuppressed (Vetvicka et al., 1996; Yun et al., 2003; Brown and
Gordon, 2003; Brown and Gordon, 2005); however research is extremely limited in
improvements in immune function in healthy, free-living, human populations. Because
the immune system can improve with moderate exercise (Nieman, 2003;) but may see
deterioration with excessive and/or vigorous exercise (Davis et al., 1997; Ceddia and
Woods, 1999; Pederson and Hoffman-Goetz, 2000; Nieman, 2000; Nieman, 2003), it is
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difficult to determine the effects of ß-glucan in improving immune function in free-living
humans (Nieman et al., 2008); especially young, active humans. It is also possible that
this phenomenon is problematic with lack of or excessive sleep and/or psychological
stress. ß-glucan comes in many different forms such as oat, barley, rye, wheat, and yeast.
Oat ß-glucan has been studied far more than any of the other forms and has been shown
repeatedly to aid human physiological function in many ways (Jenkins et al., 2002;
Vetvicka et al., 1996; Yun et al., 2003; Brown and Gordon, 2003; Brown and Gordon,
2005). The study of yeast ß-glucan is on the rise, but has struggled to demonstrate
significant benefits at the level of oat ß-glucan.
Because college-aged students generally have high amounts of perceived stress,
vary in their amount of sleep and physical activity, and are more often exposed to viral
and fungal infections due to group living situations, they may be an ideal population to
examine symptoms of URTI and the potential benefits of ß-glucan supplementation.

Problem One

The first purpose of this study is to examine the effects of a yeast β-glucan
supplement on symptoms of upper respiratory tract infection in college-aged males.
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Problem Two

The second purpose of this study is to examine how time spent in sleep,
psychological stress, time spent in physical activity, and exposure relate to duration and
severity of an upper respiratory tract infection.

Research Hypotheses

Evaluation of Upper Respiratory Tract Infections and β-glucan

The present study used a reliable and valid survey to evaluate symptoms of URTI.
Determination of an URTI was defined by the use of the survey as well as additional
questions asked of the subjects. Subjects were asked what they believed was the cause of
their illness or symptoms in addition to the questions on the survey about symptoms of
URTI. If subjects believed the cause was an URTI, then the day was defined as a
symptom day. If, however the subject only met the criteria of the survey, the day was
defined as a sick day. The survey defined an URTI as two or more symptoms observed
on any given day. Episodes were defined as symptoms persisting for more than seven
days. We hypothesized that the individuals receiving the β-glucan supplement would not
have a:
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1.

Reduced total number of symptom days of upper respiratory tract
infection.

2.

Reduced symptom day severity score of upper respiratory tract infection.

3.

Reduced symptom day maximum severity score of upper respiratory tract
infection.

4.

Reduced symptom day quality of life score of upper respiratory tract
infection.

5.

Reduced symptom day maximum quality of life score of upper respiratory
tract infection.

6.

Increased number of days before the first symptom day past 3 days of
supplementation

7.

Reduced total number of sick days of upper respiratory tract infection.

8.

Reduced sick day severity score of upper respiratory tract infection.

9.

Reduced sick day maximum severity score of upper respiratory tract
infection.

10.

Reduced sick day quality of life score of upper respiratory tract infection.

11.

Reduced sick day maximum quality of life score of upper respiratory tract
infection.

12.

Increased number of days before the first sick day past the first three days
of supplementation.

13.

Reduced total number of symptom episodes of upper respiratory tract
infection.
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14.

Reduced symptom episode severity score of upper respiratory tract
infection.

15.

Reduced symptom episode quality of life score of upper respiratory tract
infection.

16.

Reduced symptom episode duration of upper respiratory tract infection.

17.

Reduced symptom episode maximum duration of upper respiratory tract
infection.

18.

Increased number of days before the first symptom episode past the first 3
days of supplementation.

19.

Reduced total number of sick episodes of upper respiratory tract infection.

20.

Reduced sick episode severity score of upper respiratory tract infection.

21.

Reduced sick episode quality of life score of upper respiratory tract
infection.

22.

Reduced sick episode duration of upper respiratory tract infection.

23.

Reduced sick episode maximum duration of upper respiratory tract
infection.

24.

Increased number of days before the first sick episode past the first 3 days
of supplementation.
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Evaluation of Upper Respiratory Tract Infections and Factors that Affect URTI Risk

1.

We hypothesized that individuals who sleep less will not have higher
severity scores and effect on quality of life scores throughout the duration
of an episode than those who sleep more.

2.

We hypothesized that individuals who have higher stress scores will have
higher severity scores and effect on quality of life scores throughout the
duration of an episode than those who have lower stress scores.

Rationale for Hypothesis Two

Previous research has demonstrated that psychological stress increases
blood cortisol levels (Tortora and Derrickson, 2006). Cohen et al., 1991
presented that increased blood cortisol levels and psychological stress are
associated with an increased risk of acute infections of the upper
respiratory tract.

3.

We hypothesized that individuals who get moderate amounts of exercise
prior to and during an episode will have lower severity scores and quality
of life scores through the duration of an episode than those who are
generally sedentary and those who get vigorous amounts of exercise.
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Rationale for Hypothesis Three

Previous research has shown that physical activity has varying effects on
the immune system. Generally, regular, moderate exercise improves
immune function while extended vigorous exercise as well as no exercise
has adverse effects on immune function (Nieman, 2003; Woods, 2005;
Nieman, 2007).

4.

We hypothesized that individuals who have higher exposure scores prior
to an episode will not have higher severity scores and quality of life
throughout the duration of an episode.

Significance of the Study

Previous research has concluded that excessive amounts of time and money are
wasted every year attempting to prevent and remedy symptoms of upper respiratory tract
infection. ß-glucan has been demonstrated to improve immune function in many
populations. Studies show that lab measurements to indicate upper respiratory tract
infections are not as accurate when compared to the individual’s perceived symptoms of
upper respiratory tract infection (Jackson et al., 1957; Barrett et al., 2002; Barrett et al.,
2005; Barrett et al., 2007). Barrett et al. (2007) found that treatments of the common cold
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such as antihistimine, decongestants, steroids, zinc, vitamin C, and Echinacea did not
decrease illness duration and ultimately cold remedies offer only limited benefits. Most
research agrees that oat ß-glucan can help prevent infection of the upper respiratory tract
in clinically diagnosed immunosuppressed individuals, however, to our knowledge no
research has succeeded in showing that a yeast ß-glucan supplement can improve
symptoms of upper respiratory tract infection in relatively healthy populations.

Rationale for the Study

Collecting survey data daily may allow for a more accurate picture of URTI in
male college students throughout a semester. Examining whether or not ß-glucan can
prevent these symptoms may have implications for maintaining immune function in
healthy, free-living populations. Also, this research may provide a better understanding
of how much each of the risk factors for URTI plays a role in preventing and fighting
URTI.
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Limitations

i/Non-randomized sample. Subjects were not from a randomized sample. Subjects were
recruited from The University of Montana campus. Most were from classes in the
Department of Health and Human Performance.

ii/Participants. Although we aimed for socioeconomic diversity, our participants were
volunteers and may not have been representative of cold-sufferers.

iii/Age and Sex. The data collected only applies to college-aged males.

iv/Survey. Qualitative, self-reported survey data, may have been biased.

iv/Free-living individuals. We did not control for lifestyle habits or dietary habits.
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Delimitations

i/Type of subjects. Due to the large number of potential participants in the study
population, the population involved in the current study focused only on students at The
University of Montana.

ii/Age of subjects. Due to problems with getting consent for persons under the age of 18,
our age range began at 18 years. Due to the differences in pulmonary function seen in
older populations, our age range ended at 41 years.

iii/Survey. Survey instruments used only scale items and did not include many openended response items.
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Definition of Terms

Immune System: the integrated body system of organs, tissues, cells, and cell products
such as antibodies that differentiates self from non-self and neutralizes potentially
pathogenic organisms or substances.
Immunosuppression: the inhibition of the normal immune response because of disease,
the administration of drugs, or surgery.

Resistance: the ability to ward off damage or disease through immune defenses.

Dietary Supplement: a product taken orally that contains one or more ingredients that
are intended to supplement one's diet.

Susceptibility: vulnerability or lack of resistance to illness.

Upper respiratory tract infections: are the illnesses caused by an acute infection which
involves the upper respiratory tract: nose, sinuses, pharynx or larynx.
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Chapter Two: Review of Literature

β-glucan

Fiber is a necessary part of the human diet. ß-glucan is a type of fiber that is
soluble, viscous, and fermentable. There are six forms of ß-glucan found in the cell walls
of green plants and some fungi. Glucans are glucose polysaccharides containing one kind
of simple sugar, or monosaccharide, glucose. ß-glucans are made up of ß-bonds, which
are more difficult to digest for some mammalian digestive tracts.
The structure of ß-glucan is slightly different from source to source. Generally, ßglucans are composed of linear (β-1  3) backbone chains with different side chains (β-1
 4 or β-1  6) (Castro et al., 2007). Cellulose is a source of (β-1  4)-ß-glucan,
which is a long and linear polymer that is difficult for humans to digest. Both oat and
barley have mixed-linkage (β-1  3, β-1  4)-ß-glucans and are easily fermented in the
intestine. Other grains, such as wheat, rye, and rice, contain small amounts of ß-glucan.
Microbial (β-1  3)-ß-glucan is another component of cell walls or can be secreted by
microorganisms growing on or in plants, such as yeast. Mushrooms also contain (β-1 
3)-ß-glucans, with (β-1  6) side chains.
The percentage and distribution of ß-glucan in the source may also determine its
structure. Mushrooms typically contain 0.3% ß-glucan, whereas the distribution of the
carbohydrate in grains range between 17% and 46%. Generally, soluble ß-glucan content
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is much higher in cereals than insoluble ß-glucan; in mushrooms and microorganisms this
ratio varies (Manzi and Pizzoferrato, 2000).
ß-glucan chemical structure is made up of mostly beta-bonds. Human digestive
enzymes can generally only break down α-bonds easily. The human body can only break
down these beta-bonds in mastication and in the lower gastrointestinal tract by bacterial
enzymes (Whitney and Rolfes, 2002). Soluble ß-glucans are theorized to translocate
from the gastrointestinal tract into systemic circulation by uptake of Peyer’s patches,
clusters of lymphoid tissue in the lower gastrointestinal tract (Rice et al., 2005).
All forms of ß-glucan have demonstrated both null effect and improvements in all
populations; rarely has it been shown to induce damage. One study did find that using an
altered form of oat ß-glucan, rather than leaving the ß-glucan in its most natural state,
induced statistically significant damages to pulmonary function in immunosuppressed
mice (Young et al., 2003). Even toxicity level studies have failed to show significant
results for toxic levels of consumed or injected ß-glucan. Research in many areas of
illness and chronic disease have recently been investigating potential benefits of different
derivatives of ß-glucan supplementation.

Oat and Yeast ß-glucan
Cholesterol

Oat ß-glucan has been studied in clinical trials, and has been identified as the
component responsible for the significant cholesterol-lowering properties in oats; the
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most attention is given to oat ß-glucan in its effectiveness to decrease low-density
lipoprotein (LDL) cholesterol in human populations. After 5 weeks of orally ingesting
2.5 g of oat-derived ß-glucan twice daily, men and women were both seen to have lower
LDL cholesterol than the control group (Naumann et al., 2006). Similarly, Jenkins et al.
(2002) found that hyperlipidemic patients who consumed more soluble fiber containing
oat ß-glucan or psyllium (8 g per day or more) in their diet over a one month period
decreased their LDL cholesterol significantly more than those who did not consume a
high amount of soluble fiber in their diet.
Yeast, has also been shown to lower LDL cholesterol in hyperlipidemic human
populations. Obese male patients were given 7.5 g of yeast-derived ß-glucan twice daily
for a two-week period and lipid panels were measured. Results showed a significant
decrease in LDL cholesterol (Nicolosi et al., 1999).
These complimentary results suggest that oat and yeast ß-glucan may follow
similar pathways or may have similar mechanisms for decreasing LDL cholesterol in
humans. This parallel may indicate that the two may be comparable in affecting different
aspects of human physiology.

Cancer

Oat ß-glucan may also help in cancer therapy by enhancing lung macrophage
activity. Murphy et al. (2004) discovered that oat ß-glucan can decrease the spread of
melanoma cells and that these effects may be mediated by macrophage activity. Mice

17

received 0.6 mg oat ß-glucan dissolved per 1 ml of drinking water daily for 10 days
before tumor administration. Results of this research show that the mice that were given
an oat ß-glucan saw a significantly lower metastatic spread rate of the tumors.
Yeast ß-glucan was shown to combine with and enhance an antibody, which
fights a vascular endothelial cancer found in the human cervix (Salvador et al., 2008).
The protocol consisted of screening and removing active tumor cells from living human
females and implanted in immunodeficient mice. Mice that received supplementation of
1.2 mg of yeast-derived ß-glucan twice a week via intravenous injection, showed
significantly reduced tumor size when compared with those that did not receive the
supplementation. The authors of this research suggest that, if the mechanism is similar in
humans, cancer growth might be delayed by intravenous injection of yeast ß-glucan.
Hong et al. (2004) also found that certain types of cancer cells were completely
eliminated when yeast ß-glucan was orally administered to a similar murine population.
These mice were given 400 µg of the yeast ß-glucan daily for three weeks.
Supplementing with a yeast ß-glucan was also shown to stimulate proliferation
and activation of peripheral blood monocytes in patients with advanced breast cancer
(Demir et al., 2007). The patients in the research were newly diagnosed or relapsed with
metastatic breast cancer. Each subject orally ingested 10 mg of yeast-derived ß-glucan
for two weeks. Peripheral blood was drawn at day 0 and day 15. Although the majority
of cancer fighting immune cells did not improve in any way, blood monocytes were
shown to increase in number and amount of activity. This study suggests that short-term
treatment with yeast ß-glucan may improve blood monocyte number and function, which,
in turn, indicates an improvement in immune function. Both mice and human
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populations suffering from various cancers have been shown to benefit from a yeast ßglucan supplement.
Supplementation with an oat or yeast ß-glucan have both been successfully used
in murine populations to slow tumor development. The addition of human research
demonstrating an improvement in blood monocyte number and function with yeast ßglucan implies that if the mechanisms and/or pathway of ß-glucan is similar in humans
and mice, tumor activity may be semi-controlled with the aid of an oat or yeast ß-glucan
supplementation. Also, because this research supports that ß-glucan is translocated from
the gut in humans into the blood stream, research in other areas of immune function are
being conducted.

Bacterial and Viral Infections

Oat ß-glucan has also been found to fight certain infections in murine populations
(Yun et al., 2003). In this study mice were administered either intragastrically or
intraperitoneally 3 mg of oat ß-glucan every other day for 10 days. At 10 days, mice
were exposed to either Staphylococcus aureus or Eimeria vermiformis. These bacteria
are known to cause similar, common infections in both mice and humans. The
experimental group was shown to have a lower mortality rate than the control group as
well as an increased resistance to developing any infection. This suggests that short-term
treatment with an oat ß-glucan, prior to exposure, can enhance immune function against
common infections in mice.
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Similarly, Murphy et al. (2008) administered mice with 0.8 mg oat ß-glucan
dissolved per 1 ml of drinking water for 10 days before inoculation with a virus. In both
studies, mice that orally ingested the oat ß-glucan demonstrated benefits in their immune
function.
Promising research results investigating benefits of supplementation with oat ßglucan to aid in fighting infections has been shown. Recently research has started to
evaluate benefits of a yeast ß-glucan supplement in fighting infections, mainly URTI.
Because similar results are seen between oat and yeast ß-glucan supplementation in
cancer and cholesterol research in both mice and humans it is suggested that the two
follow similar pathways in the murine and human bodies, have similar mechanisms in the
two organisms, or both. With the addition of successful research in showing that oat ßglucan supplementation is beneficial to the murine population in aiding the immune
system in fighting infections, it is necessary to explore the murine and human population
and effects of both oat and yeast ß-glucan supplementation in specific infections.

Upper Respiratory Tract Infections

URTI and their symptoms are common and generally do not result in
hospitalization or fatality. However, because they are so common, money and time are
spent excessively every year to prevent and treat symptoms of URTI (Bramley et al.,
2002). The common cold, as URTI are generally known, can cause measurable,
significant declines in quality of life (Linder and Singer, 2003).
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There are many suggestions as to why immune function is suppressed enough to
allow an URTI to thrive. Nieman (2007) concludes that excessive physical activity is
enough of a physiological stress that the body experiences many changes in immune
function: drop in natural killer cells and T cells, decrease in T cell function, decrease in
nasal neutrophil phagocytosis and mucociliary clearance, etc. Because of these changes,
the body is much more susceptible to upper respiratory tract infections. Carbohydrate
feeding may help the immune system in some ways to protect it from the damages caused
by prolonged, vigorous exercise, but may not aid in preventing upper respiratory tract
infections (Nieman, 2007).

ß-glucan and Upper Respiratory Tract Infections
Murine Subjects

Mice are a useful model for studying effects on the immune system and URTI.
They appear to be susceptible to similar stimuli for immunosuppression to humans. For
example, both psychological and physical stressors are shown to increase risk of upper
respiratory tract infections in mice (Hunzeker et al., 2004). Previous research has shown
that mice participating in a single bout of prolonged, vigorous exercise are at a higher risk
for upper respiratory tract infections than those who either underwent a short-term
exercise or no exercise (Davis et al., 1997). The results of this particular study
demonstrated that lung alveolar macrophage activity was reduced in the mice that
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exercised for long durations. This research suggests that mice could serve as a model for
risk of URTI in humans.
ß-glucan and its effects on immune function and URTI research began with mice
models. Oat ß-glucan has been shown to enhance immunity in mice and prevent
infection of the upper respiratory tract. ß-glucan may play a key role in offsetting the risk
for infection following exercise stress in mice (Murphy et al., 2008). This research
examined lung macrophage activity and proliferation in mice that were supplemented
with oat ß-glucan. The mice were given 0.8 mg of oat ß-glucan 10 days prior to trial
days. One group of mice was exercised to volitional fatigue three consecutive days after
supplementation days. Depletion of lung macrophages negated the positive effects of the
oat ß-glucan post exercise. Results of this study demonstrated that lung macrophage
activity is partially responsible for mediating supplemental effects of oat ß-glucan on
susceptibility to URTI. Because macrophages and lymphocytes are important for
immune function, these studies imply ß-glucan may improve the number or function of
these immune cells, which may help fight or prevent the prevalence of URTI.
Davis et al. (2003) reported that only moderate exercise and not supplemental oat
ß-glucan significantly improved immune function. Similar to other ß-glucan research
done in mice, the subjects were given 0.6 mg of oat ß-glucan dissolved into every 1 ml of
drinking water daily for 10 days prior to inoculation with a herpes virus. Mice were
exercised on a treadmill for 1 hour per day for 6 days after the 10-day supplementation
period with oat ß-glucan. Results showed no significant improvement with the oat ßglucan alone, but with exercise there were significant improvements in immune function.
With the same research group, Murphy et al. (2007) demonstrated slightly
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different results. Male mice were given 0.6 mg of oat ß-glucan dissolved into every 1 ml
of drinking water daily for 10 days prior to exercise trials. Mice were divided into six
groups (control, oat ß-glucan with no exercise, moderate exercise, oat ß-glucan with
moderate exercise, fatiguing exercise, and oat ß-glucan with fatiguing exercise). Results
of this study showed that moderate exercise and oat ß-glucan supplementation increased
neutrophil burst activity. The control group and fatiguing exercise groups did not see an
increase in immune cell function. There was no additive benefit of the moderate exercise
and the oat ß-glucan supplementation.
These combined results suggest that supplementing with an oat ß-glucan is
beneficial in mice immunocompromised by infection or tumor as well as healthy
moderately exercised mice.
Willment et al. (2001) found that the human receptor of ß-glucan is both
structurally and functionally similar to the mouse receptor. The mouse ß-glucan receptor,
Dectin-1, is a type II transmembrane protein, as is the corresponding receptor in humans.
These receptors are capable of recognizing a variety of (β-1  3, β-1  6) ß-glucans and
can also recognize intact yeast. As we have found that both the mouse and human
receptors recognize ß-glucans. The human and mouse ß-glucan receptors differ in that the
transcript encoding the human receptor is alternatively spliced, which does not seem to
have an effect on the ability of the receptor to recognize ß-glucan or intact yeast
(Willment et al. 2001). Other research found specific receptors of fungal ß-glucan
(Dectin-1) were also functionally similar to the molecule found in mice (Herre et al.,
2004). The receptors were shown to be similar on the surface of both mouse and human
leukocytes and that they both recognize β-glucan. The receptor recognizes and binds
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cells of the immune system (T-lymphocytes and leukocytes). This evidence, along with
the beneficial effects of oat ß-glucan in mice, suggests that the effects of ß-glucan as aids
in proliferation of immune cells in mice should have similar effects in humans.

Human Subjects

Human research has found that oat ß-glucan offset increased upper respiratory
tract infection risk associated with exercise stress (Ceddia and Woods, 1999; Davis et al.,
2004). Because exercise can both improve and degenerate immune function, it is
difficult to demonstrate the effects of a ß-glucan supplement in healthy, free-living
populations.
Similar research has been conducted in humans as well with conflicting results
(Nieman et al., 2008). Trained male cyclists were randomized to an experimental or
control group. The experimental group received 5.6 g per day of an orally administered
oat ß-glucan supplement 2 weeks before, during, and1 day after 3 day trial. Trial
consisted of cycling for 3 hours per day at approximately 57% maximal watts. URTI
symptoms were monitored during supplementation and for 2 weeks after trial. Blood
samples were collected before and after 2 week of supplementation, immediately after the
3-h exercise bout on day 3, and 14 hours after exercise. Immune cellular activity
associated with fighting UTRI was assessed and no significant differences were found
between the two groups.
The similarities seen between oat and yeast ß-glucan in both murine and human
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populations suggest that similar effects may be seen in other areas of physiology, such as
immune function. Research on the effects of yeast ß-glucan on symptoms of URTI are
currently lacking in beneficial results. URTI pose a complicated threat to the immune
system in that symptoms are difficult to diagnose as well as the cause could be viral or
bacterial infection. Also, because free-living humans are exposed to much more diverse
threats to their immune systems that lab living mice, it is likely more difficult to see
effects of a ß-glucan supplement in human populations. It is necessary to understand the
human immune system and factors that may compromise its function in order to
investigate whether a yeast ß-glucan could potentially benefit healthy, free-living
humans.

Immune System Function

The immune system is the primary defense system of the body to ward of harmful
agents and is vital in maintaining homeostasis. This system is comprised of two
developmental components: innate immunity and specific immunity. Innate immunity is
present at birth and provides immediate, but general protection against invasion by a
number of different pathogens. Specific immunity develops more slowly and becomes a
response mechanism activated by a specific invader. The skin and mucous membranes of
the human body provide the first line of defense and protection against these invaders.
Gastric fluids, at a high acidity, allow digestion of food and kill many different types of
bacteria found in the food ingested. Antimicrobial proteins, phagocytes (neutrophils and
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macrophages), natural killer cells, inflammation, and fever comprise the second line of
defense against pathogens (Tortora and Derrickson, 2006). The lymphatic system,
working together with other systems of the body, makes up the immune system of the
human body (Tortora and Derrickson, 2006).
If the first line of defense fails to identify and ward off foreign invaders, the
second line of defense will take over. While inflammation and fever work to eliminate a
threat, antimicrobial proteins are produced in a number of ways by lymphocytes,
macrophages, and fibroblasts and allow cells to prevent further replication of viruses
(Medzhitov and Janeway, 1997). Other proteins activated can cause cytolysis, or
bursting, of microbes, promote phagocytosis, and contribute to inflammation. Some
proteins inhibit growth of bacteria by limiting the amount of iron available. Natural killer
cells attack any cells that display abnormal proteins. These cells release a wide range of
cell destruction enzymes and proteins in order to eliminate a threat. Phagocytes target
and ingest microbes or other cellular debris. These cells can wander to sites of infection
or remain stationary in different specific tissues. Alveolar macrophages reside in lung
tissue to prevent damage by foreign particles and protect against other unwanted
pathogens (Medzhitov and Janeway, 1997; Tortora and Derrickson, 2006).

Factors that Affect Immune Function

A disease or illness can be a result of a failure of the immune system to protect
the body from pathogens or cancer cells. Even though the immune system is complex
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and highly developed, there are many pathogens that manage to surpass the body’s
defenses, often resulting in disease or illness. There are many behaviors which can result
in a decline in immune function.

Nutrition Behaviors

Malnutrition and other poor nutritional habits can impact generalized host defense
mechanisms (Beisel, 1996). Children and the elderly are more susceptible to malnutrition
than adults; however, immune function can be altered through all stages of life with poor
nutrition habits, which include excessive nutrient intakes (Beisel, 1996). Beisel (1996)
concluded that lack of protein and vitamin A were whereas excess in caloric intake
consisting of high fat content were both associated with immune compromise.

Sleep Behaviors

Sleep is a basic biological need in humans. It is well known that sleep deprivation
can have adverse effects on brain and motor function (Tortora and Derrickson, 2006).
There is some debate in research as to whether partial or total sleep deprivation can be
conceptualized as only being immunosuppressive (Dinges et al., 1995). Experiments
generally find significant changes in blood levels of immunity cells; however, not all
changes in these levels can be considered negative for the immune system (Dinges et al.,
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1995). Although there is a lack of conclusive evidence that sleep deprivation alone has
adverse affects on the immune system, it may indirectly influence immune dysfunction
with the combination of increased adrenal catecholamine release in the blood.

Psychological Stress

Cortisol is a hormone that has been associated with mental stress. Cortisol has
different effects on the human body including changes in the body such as inhibition of
immune system activity (Tortora and Derrickson, 2006). Psychological stress is also
associated with an increased risk of acute infections of the upper respiratory tract (Cohen
et al., 1991). Sleep deprivation has been shown to cause cortisol blood level increases
(Lac and Chamoux, 2003). This combined evidence suggests that sleep deprivation can
lead to an increase in psychological stress and cortisol, leading to a decline in immune
function (Glaser and Kiecolt-Glaser, 2005; Fukuda and Morimoto, 2001; Kiecolt-Glaser,
1999).

Physical Stress

Adrenal catecholamines are other stress hormones similar to cortisol in that they
are all released from the adrenal cortex. Physical and psychological stressors alter
plasma catecholamine levels in different ways (Landmann et al., 1984). Kohut et al.
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(1998) found evidence that an increased release of adrenal catecholamines may cause a
decrease in macrophage antiviral function following exercise. Physical activity has
sundry effects on the human body, which are dependent on intensity, frequency, and
duration of sessions (Woods, 2005). Generally, regular, moderate exercise improves
immune function (Tortora and Derrickson, 2006; Gleeson, 2007) and is recommended as
a strategy for managing stress (Nguyen-Michel et al., 2006), while extended, vigorous
exercise and no exercise may have adverse affects on the immune system (Nieman, 2003;
Woods, 2005; Nieman, 2007). Immune function declines in similar ways between elite
endurance athletes and a sedentary population (Nieman et al., 1995), which suggests that
sedentary and extremely active populations may have similar immune function declines
overall.
Because of the wide range of changes seen in immune function due to sleep
deprivation, psychological stress, physical activity, and poor nutrition habits, it is difficult
to discern what the true mechanisms behind these changes are. The evidence is
conclusive, however, that both positive and negative changes in immune function are
experienced due to any combination of these stressors. It is beneficial to understand the
variations between the different stressors and their effects on immunity. Kiecolt-Glaser
et al. (2002) discussed that that immune dysregulation may be one of the core
mechanisms for a spectrum of conditions associated with cardiovascular disease,
osteoporosis, arthritis, Type II diabetes, certain cancers, and other older-age-related
functional declines.
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College Students and Immune Function

Stress is a part of every person’s life. As previously discussed, too much stress
can have adverse affects on immune function. College students experience a
considerable amount of stress due to educational workload, financial difficulties, peer
pressure, development of future plans, etc. Generally, colleges require that a student live
in a campus dorm for at least the first two years of school. These close living conditions
expose students to many different viral and bacterial infections, many of which affect the
upper respiratory tract. Research done in the 1990s suggested that college students’
amount of stress is negatively associated with self-concept, self-esteem (Goldman and
Wong, 1997), and perceptions of performance in school (Garden, 1991). Most research
supports the conclusion that regular physical activity is a viable means of reducing stress
in college students; however it is believed that extreme levels of stress discourages
physical activity due to lack of time or energy in many college students, thus increasing
perceived stress levels (Nguyen-Michel et al., 2006).
College students also have variable sleep patterns compared to other populations.
Trockel et al. (2000) observed that college students with the most variable sleep patterns,
particularly time of rising, accounted for the largest amount of variance in grade point
average in college students living in residence halls. Previous research has found that
college students with poor sleep quality had greater schedule variability in the timing of
social rhythms and activities with active social environment (Carney et al., 2006). The
authors of the previous study suggested also that quality of sleep is highly correlated with
stress levels and thus, indirectly risk of URTI.
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Sleep, stress, physical activity, nutritional behaviors, and level of immune
function are all factors that, when compromised, become a risk factor for developing an
URTI. Because of the variability of all of these factors, with the exception of immune
function, college students are at a high risk for developing URTI. Because college
students are at high risk for UTRI and have healthy functioning immune systems, they
represent a good sample population of healthy, free-living individuals.
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Chapter Three: Methodology

Setting
All data collection was conducted through the Montana Center for Work
Physiology and Exercise Metabolism on the campus of The University of Montana,
Missoula, MT. Survey data was collected using a secured online survey program
(surveymonkey.com).

Subjects
Approximately 175 males were initially recruited as the subjects in this
investigation. Of these recruits, 81 served as the subjects in the study. These subjects
were recruited through dorm communications, class recruitment presentations, and signup in the University Center at The University of Montana. Prior to participation, all
subjects completed an Institutional Review Board (IRB) approved informed consent
form.

Descriptive Data
Descriptive Data was collected using four different methods. (1) A background
survey was completed by each subject which included age, gender, marital status, living
conditions, injuries which limit physical activity, dieting, caffeine intake, tobacco use,
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and estimated consumption of foods with high amounts of ß-glucan; (2) a daily survey
completed by each subject during the twelve week study included twenty-four hour sleep
record in hours, twenty-four hour physical activity time in minutes, and twenty-four hour
stress level; and (3) an optional post study survey completed by the majority of subjects
included current height, current weight, estimated weight prior to study, how often and/or
easily subject accrues illness, and whether subject believed they were taking 250mg of ßglucan or placebo (rice flour).

Exclusion Criteria
Subjects were excluded from the study results if (1) they were not within the 1841 year age requirement throughout the study; (2) they did not complete the background
survey; or (3) they did not complete at least 75% (63) of the daily surveys.

Instrumentation

WURSS
The Wisconsin Upper Respiratory Symptoms Survey (WURSS) was developed as
an evaluative illness specific quality-of-life instrument (Barrett et al., 2008). The
construct validity of the WURSS-44, a forty-four question version of the survey, is
supported by measures of reliability and responsiveness of subjects (Barrett et al., 2005).
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This survey looks at thirty-two symptoms of upper respiratory tract infection, ten
functional quality-of-life items, one global illness severity item (How sick do you feel
today?), and one item assessing global change (Compared to yesterday how do you feel?)
(Barrett et al., 2005; Barrett et al., 2002). The survey allows subjects to score their
symptoms using a seven-point scale (0 = none, 1 = very mild, 3 = mile, 5 = moderate, 7 =
severe).

Data Collection
Each subject signed an Institutional Review Board (IRB) approved informed
consent form prior to participation in the study. Subjects were asked to take either a βglucan 250mg supplement or a placebo (rice flour) daily. Distribution of supplement and
placebo was done in a double-blind fashion. Along with taking the daily supplement or
placebo, each subject filled out an online survey (surveymonkey.com) which includes
questions about sleep, stress, physical activity, exposure to illness, includes the WURSS,
and asks a final question about the subject’s belief of the cause of any symptoms (flu,
cold, allergies, etc.).

Operational Definitions
An upper respiratory tract infection symptom day was defined as any day that a
subject (1) scored above a zero on the global illness severity question, (2) scored above a
zero on at least two of the thirty-two symptoms of upper respiratory tract infection, and
(3) believed that their symptoms were due to a cold.
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Symptom day severity of an upper respiratory tract infection symptom day was
defined as the total sum of all thirty-two symptom scores from the WURSS for each
symptom day of a subject.

Symptom day severity max of an upper respiratory tract infection symptom day
was defined as the highest symptom day severity score for each individual subject.

Symptom day quality of life severity of an upper respiratory tract infection
symptom day was defined as the total sum of all ten effect on quality of life scores from
the WURSS for each symptom day of a subject.

Symptom day quality of life severity max of an upper respiratory tract infection
symptom day was defined as the highest symptom day quality of life severity score for
each individual subject.

Number of days until first symptom day was defined as the total number of days
prior to the first symptom day past the first seven days for each individual subject.

An upper respiratory tract infection sick day was defined as any day that a subject
(1) scored above a zero on the global illness severity question, (2) scored above a zero on
at least two of the thirty-two symptoms of upper respiratory tract infection, and (3)
believed that their symptoms were due to allergies, flu, cold, or other (specified).
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Sick day severity of an upper respiratory tract infection symptom day was defined
as the total sum of all thirty-two symptom scores from the WURSS for each sick day of a
subject.

Sick day severity max of an upper respiratory tract infection symptom day was
defined as the highest sick day severity score for each individual subject.

Sick day quality of life severity of an upper respiratory tract infection symptom
day was defined as the total sum of all ten effect on quality of life scores from the
WURSS for each sick day of a subject.

Sick day quality of life severity max of an upper respiratory tract infection
symptom day was defined as the highest sick day quality of life severity score for each
individual subject.

Number of days until first sick day was defined as the total number of days prior
to the first sick day past the first seven days for each individual subject.

An upper respiratory tract infection symptom episode was defined as a subject (1)
scored above a zero on the global illness severity question for seven or more consecutive
days, (2) scored above a zero on at least two of the thirty-two symptoms of upper
respiratory tract infection, and (3) believed that their symptoms were due to a cold. The
end of a symptom episode was defined as two or more consecutive days where the
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subject scored a zero on the global illness severity question. If there was only one day
when the subject scored a zero on the global illness severity question followed by one or
more days of a score above zero with two or more symptoms, the episode was considered
to be continuing. If there were less than two symptoms in this case, the episode was
classified as ended on the most recent symptom day when the subject scored above a zero
on the global illness severity question with two or more symptom scored above zero.

Symptom Episode symptom severity of an upper respiratory tract infection
episode was defined as the average symptom day severity scores for each symptom
episode of a subject.

Symptom Episode quality of life severity of an upper respiratory tract infection
episode was defined as the average symptom day quality of life severity scores for each
symptom episode of a subject.

Symptom Episode duration of an upper respiratory tract infection episode was
defined as the total number of symptom days in a symptom episode. This definition also
included non-symptom days that are still considered part of a symptom episode.

Symptom Episode duration max of an upper respiratory tract infection episode
was defined as the highest symptom episode duration experienced by each subject.
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Number of days until first symptom episode was defined as the total number of
days prior to the first symptom episode past the first seven days for each individual
subject.

An upper respiratory tract infection sick episode was defined as a subject (1)
scored above a zero on the global illness severity question for seven or more consecutive
days, (2) scored above a zero on at least two of the thirty-two symptoms of upper
respiratory tract infection, and (3) believed that their symptoms were due to allergies, flu,
cold, or other (specified). The end of a sick episode was defined as two or more
consecutive days where the subject scored a zero on the global illness severity question.
If there was only one day when the subject scored a zero on the global illness severity
question followed by one or more days of a score above zero with two or more
symptoms, the episode was considered to be continuing. If there were less than two
symptoms in this case, the episode was classified as ended on the most recent sick day
when the subject scored above a zero on the global illness severity question with two or
more symptom scored above zero.

Sick Episode symptom severity of an upper respiratory tract infection episode was
defined as the average symptom day severity scores for each sick episode of a subject.

Sick Episode quality of life severity of an upper respiratory tract infection episode
was defined as the average symptom day quality of life severity scores for each sick
episode of a subject.
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Sick Episode duration of an upper respiratory tract infection episode was defined
as the total number of symptom days in a sick episode. This definition also included nonsymptom days that are still considered part of a sick episode.

Sick Episode duration max of an upper respiratory tract infection episode was
defined as the highest sick episode duration experienced by each subject.

Number of days until first sick episode was defined as the total number of days
prior to the first sick episode past the first seven days for each individual subject.

Data from the WURSS was collected daily to determine, as defined above, the (1)
total number of symptom days for each subject, (2) average symptom day severity for
each subject, (3) symptom day severity max for each subject, (4) average symptom day
quality of life severity for each subject, (5) symptom day quality of life severity max for
each subject, (6) total number of days prior to first symptom day for each subject (7) total
number of sick days for each subject, (8) average sick day severity for each subject, (9)
sick day severity max for each subject, (10) average sick day quality of life severity for
each subject, (11) sick day quality of life severity max for each subject, (12) total number
of days prior to first sick day for each subject (13) total number of symptom episodes for
each subject, (14) average symptom episode severity for each subject, (15) average
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symptom episode quality of life severity for each subject, (16) average symptom episode
duration for each subject, (17) symptom episode duration max for each subject, (18) total
number of days prior to first symptom episode for each subject (19) total number of sick
episodes for each subject, (20) average sick episode severity for each subject, (21)
average sick episode quality of life severity for each subject, (22) average sick episode
duration for each subject, (23) sick episode duration max for each subject, (24) total
number of days prior to first sick episode for each subject

Compliance of subjects

The study coordinator monitored subject compliance by telephoning or emailing
subjects who missed three or more consecutive surveys. Technological problems were
resolved or subject was excluded at their own discretion. Surveys were resent twice to
non-responded subjects within two weeks of the originally sent daily survey date.

Statistical Procedures

Background descriptive data were analyzed using an independent t-test for age,
height (inches), pre-study weight (kg), post-study weight (kg), weight change (kg),
physical activity time (minutes spent daily participating in aerobic, resistance, and
organized sport activities, number of high school sports, caffeine intake (mg per week
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from coffee, tea, or cola beverages), average sleep time (hours per night), average stress
level (0-10; not stressed-extremely stressed), number of allergies, average estimated βglucan intake (servings per week total and servings per week of oatmeal, cereal with oats,
other items with oats, barley, cereal with barley, other items with barley, mushrooms,
whole wheat bread, whole wheat pasta, other whole wheat foods, rye bread, other rye
foods) and will be expressed as Mean ± SD. For measures of daily sleep (hours per
night), stress (0-10; not stressed-extremely stressed), and physical activity (aerobic
exercise, resistance training, and organized sport; total physical activity minutes per day),
and average score was calculated for each variable for each subject. These measures
were analyzed using an independent t-test. Statistical significance was established at the
p < 0.05 level. These analyses were used to compare differences between the
experimental group (supplement) and the control group (placebo).

WURSS

Total number of symptom days

Each subject had a total number of symptom days from the 12-week investigation
(i.e. 0, 1, 2, etc.). These data (indicating a total number of symptom days per participant)
were analyzed using a 2-tailed, independent t-test (p < 0.05).
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Average severity of symptom days

Each subject had an average symptom day severity score from the 12-week
investigation. These data (indicating an average severity score per participant) were
analyzed using a 2-tailed, independent t-test (p < 0.05).

Average symptom day severity max

Each subject had a maximum symptom day severity score from the 12-week
investigation. These data (indicating a maximum severity score per participant) were
analyzed using a 2-tailed, independent t-test (p < 0.05).

Average quality of life severity of symptom days

Each subject had an average symptom day quality of life severity score from the
12-week investigation. These data (indicating an average effect severity of symptom
days on quality of life of each participant) were analyzed using a 2-tailed, independent ttest (p < 0.05).

42

Average symptom day quality of life severity max

Each subject had a maximum symptom day quality of life severity score from the
12-week investigation. These data (indicating a maximum effect of symptom day
severity on quality of life of each participant) were analyzed using a 2-tailed, independent
t-test (p < 0.05).

Total number of sick days

Each subject had a total number of sick days from the 12-week investigation (i.e.
0, 1, 2, etc.). These data (indicating a total number of sick days per participant) were
analyzed using a 2-tailed, independent t-test (p < 0.05).

Average severity of sick days

Each subject had an average sick day severity score from the 12-week
investigation. These data (indicating an average severity score per participant) were
analyzed using a 2-tailed, independent t-test (p < 0.05).
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Average symptom day severity max

Each subject had a maximum sick day severity score from the 12-week
investigation. These data (indicating a maximum severity score per participant) were
analyzed using a 2-tailed, independent t-test (p < 0.05).

Average quality of life severity of sick days
Each subject had an average sick day quality of life severity score from the 12week investigation. These data (indicating an average effect severity of sick days on
quality of life of each participant) were analyzed using a 2-tailed, independent t-test (p <
0.05).

Average sick day quality of life severity max

Each subject had a maximum sick day quality of life severity score from the 12week investigation. These data (indicating a maximum effect of sick day severity on
quality of life of each participant) were analyzed using a 2-tailed, independent t-test (p <
0.05).
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Total number of symptom episodes

Each subject had a total number of symptom episodes from the 12-week
investigation (i.e. 0, 1, 2, etc.). These data (indicating an average number of symptom
episodes per participant) were analyzed using a 2-tailed, independent t-test (p < 0.05).

Average symptom episode severity

Each subject had an average symptom episode severity score (average severity
scores for symptom days in each episode) from the 12-week investigation. These data
(indicating an average severity score per symptom episode of each participant) were
analyzed using a 2-tailed, independent t-test (p < 0.05).

Average symptom episode quality of life severity

Each subject had an average symptom episode quality of life severity score
average quality of life severity scores for symptom days in each episode) from the 12week investigation. These data (indicating an average quality of life severity score per
symptom episode of each participant) were analyzed using a 2-tailed, independent t-test
(p < 0.05).
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Duration of symptom episodes

Each subject had an average symptom episode duration (average of total days for
each symptom episode per participant) from the 12-week investigation. These data
(indicating an average number of days in each symptom episode per participant) were
analyzed using a 2-tailed, independent t-test (p< 0.05).

Maximum duration of symptom episodes

Each subject had a maximum symptom episode duration (symptom episode with
highest number of days for each participant) from the 12-week investigation. These data
(indicating a maximum duration of symptom episodes) were analyzed using a 2-tailed,
independent t-test (p< 0.05).
Total number of sick episodes

Each subject had a total number of sick episodes from the 12-week investigation
(i.e. 0, 1, 2, etc.). These data (indicating an average number of sick episodes per
participant) were analyzed using a 2-tailed, independent t-test (p < 0.05).
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Average sick episode severity

Each subject had an average sick episode severity score (average severity scores
for sick days in each episode) from the 12-week investigation. These data (indicating an
average severity score per sick episode of each participant) were analyzed using a 2tailed, independent t-test (p < 0.05).

Average sick episode quality of life severity

Each subject had an average sick episode quality of life severity score average
quality of life severity scores for sick days in each episode) from the 12-week
investigation. These data (indicating an average quality of life severity score per sick
episode of each participant) were analyzed using a 2-tailed, independent t-test (p < 0.05).

Duration of sick episodes

Each subject had an average sick episode duration (average of total days for each
sick episode per participant) from the 12-week investigation. These data (indicating an
average number of days in each sick episode per participant) were analyzed using a 2tailed, independent t-test (p< 0.05).
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Maximum duration of sick episodes

Each subject had a maximum sick episode duration (sick episode with highest
number of days for each participant) from the 12-week investigation. These data
(indicating a maximum duration of sick episodes) were analyzed using a 2-tailed,
independent t-test (p< 0.05).

Symptom Episodes Severity Comparison

Average severity scores for corresponding symptom episode days starting at Day
1 of each symptom episode were calculated for all symptom episode days for the two
groups. These data were analyzed using a 2-tailed, independent t-test (p<0.05).

Symptom Episodes Quality of Life Comparison

Average quality of life scores for corresponding symptom episode days starting at
Day 1 of each symptom episode were calculated for all symptom episode days for the
two groups. These data were analyzed using a 2-tailed, independent t-test (p<0.05).
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Symptom Episode Exposure Comparison

Average exposure scores for corresponding symptom episode days starting at five
days prior to Day 1 of each symptom episode were calculated for all symptom episode
days for the two groups. These data were analyzed using a 2-tailed, independent t-test
(p<0.05).

Symptom Episode Sleep Comparison

Average sleep scores for corresponding symptom episode days starting at five
days prior to Day 1 of each symptom episode were calculated for all symptom episode
days for the two groups. These data were analyzed using a 2-tailed, independent t-test
(p<0.05).

Symptom Episode Stress Comparison

Average stress scores for corresponding symptom episode days starting at five
days prior to Day 1 of each symptom episode were calculated for all symptom episode
days for the two groups. These data were analyzed using a 2-tailed, independent t-test
(p<0.05).
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Symptom Episode Physical Activity Comparison

Average physical activity scores for corresponding symptom episode days starting
at five days prior to Day 1 of each symptom episode were calculated for all symptom
episode days for the two groups. These data were analyzed using a 2-tailed, independent
t-test (p<0.05).

Sick Episodes Severity Comparison

Average severity scores for corresponding sick episode days starting at five days
prior to Day 1 of each sick episode were calculated for all sick episode days for the two
groups. These data were analyzed using a 2-tailed, independent t-test (p<0.05).

Sick Episodes Quality of Life Comparison

Average quality of life scores for corresponding sick episode days starting at five
days prior to Day 1 of each sick episode were calculated for all sick episode days for the
two groups. These data were analyzed using a 2-tailed, independent t-test (p<0.05).
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Sick Episode Exposure Comparison

Severity scores for corresponding sick episode days starting at five days prior to
Day 1 of each sick episode were calculated for all sick episode days for the two groups.
These data were analyzed using a 2-tailed, independent t-test (p<0.05).

Sick Episode Sleep Comparison

Average sleep scores for corresponding sick episode days starting at five days
prior to Day 1 of each sick episode were calculated for all sick episode days for the two
groups. These data were analyzed using a 2-tailed, independent t-test (p<0.05).

Sick Episode Stress Comparison

Average stress scores for corresponding sick episode days starting at five days
prior to Day 1 of each sick episode were calculated for all sick episode days for the two
groups. These data were analyzed using a 2-tailed, independent t-test (p<0.05).
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Sick Episode Physical Activity Comparison

Average physical activity scores for corresponding sick episode days starting at
five days prior to Day 1 of each sick episode were calculated for all sick episode days for
the two groups. These data were analyzed using a 2-tailed, independent t-test (p<0.05).

SPSS

Symptom Episode Correlation

A bivariate correlation matrix was calculated for Symptom Episode average
severity scores, quality of life scores, sleep time, stress scores, physical activity time
during the first five days of symptom episodes using SPSS (p<0.05).

Sick Episode Correlation

A bivariate correlation matrix was calculated for Sick Episode average severity
scores, quality of life scores, sleep time, stress scores, physical activity time during the
first five days of sick episodes using SPSS (p<0.05).
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Chapter Four: Results

Descriptive Data

Comparative baseline descriptive data are summarized in Table 1. There were no
significant differences between baseline descriptive data between groups. For measures
of pre-study and post-study weights there were no significant losses or gains for any
subjects, thus weight is reported as an average weight of the group calculated from the
average of each subject’s weight (kg) over the twelve weeks. Comparative subject intake
habits are summarized in Table 2. There were no significant differences between groups
with the exception of other food items consumed with oats (p = 0.02). Comparative
percent subject lifestyle characteristics are summarized in Table 3. There were no
significant differences between groups, with the exception of percentage of those who are
single (p = 0.01) and those who are partnered (p = .05).
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WURSS
Comparative data from the Wisconsin Upper Respiratory Symptom Survey are
summarized in Table 4. Yeast ß-glucan demonstrated no statistically significant effect
on the subjects for any of the variables (number of symptom days, symptom day severity
score, symptom day quality of life score, symptom day maximum severity score,
symptom day maximum quality of life score, number of sick days, sick day severity
score, sick day quality of life score, sick day maximum severity score, sick day maximum
quality of life score, number of symptom episodes, number of sick episodes, average
duration of symptom episodes, maximum duration of symptom episodes, average
duration of sick episodes, maximum duration of sick episodes, symptom episode severity
score, symptom episode quality of life score, sick episode severity score, and sick
episodes quality of life score).
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SPSS

Symptom Episodes

The severity score and quality of life score are highly correlated with each other
for symptom episodes. Stress was the only independent variable that was correlated with
both severity score and quality of life score during the first five days of the symptom
episode.

Symptom Episode Correlation
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Sick Episodes

The severity score and quality of life score are highly correlated with each other
for sick episodes. Stress was the only independent variable that was correlated with both
severity score and quality of life score during the first five days of the sick episode.

Sick Episode Correlation
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ABSTRACT
Purpose: The goal of this research was to evaluate the effects of a yeast ß-glucan on
symptoms of upper respiratory tract infection in healthy, free-living, college-aged males.
Methods: The WURSS-44, a reliable, validated survey used for determining symptoms
of upper respiratory tract infection was filled out online daily by 79 male subjects
between the ages of 18 and 40. Subjects orally ingested 250 mg capsules of either yeast
ß-glucan or placebo daily. Results: Yeast ß-glucan demonstrated no statistically
significant effect on the experimental subject population for any of the variables
associated with symptoms of upper respiratory tract infection. Conclusion: Yeast ßglucan does not significantly improve immune functioning in healthy, free-living college
aged males.

INTRODUCTION
ß-glucan is a complex carbohydrate polymer found in the cell walls of plants that
has been shown to lower cholesterol in humans (Jenkins et al., 2002), promote antitumor
activity in both humans and mice (Vetvicka et al., 1996), and improve immune function
in immunosuppressed populations of humans and mice (Yun et al., 2003; Brown and
Gordon, 2003; Brown and Gordon, 2005). Oat ß-glucan has been studied far more than
any other forms and has been shown repeatedly to aid human physiological functioning
(Jenkins et al., 2002; Vetvicka et al., 1996; Yun et al., 2003; Brown and Gordon, 2003;
Brown and Gordon, 2005).
Yun et al. (2003) argues that oat ß-glucan can alleviate certain infections in
murine populations. These mice were administered oat ß-glucan for 10 days and then
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exposed to bacteria known to cause common upper respiratory tract infections in both
mice and humans. Similarly, Murphy et al. (2008) administered mice with oat ß-glucan
dissolved per 1 ml of drinking water for 10 days before inoculation with a virus. In both
studies, mice that orally ingested the oat ß-glucan demonstrated benefits in their immune
function. The results suggest that short-term treatment with an oat ß-glucan, prior to
exposure, can enhance immune function against common infections in mice.
Supplementing with a yeast ß-glucan has been shown to stimulate proliferation
and activation of peripheral blood monocytes in patients with advanced breast cancer
(Demir et al., 2007). Both mice and human populations suffering from various cancers
have been shown to benefit from a yeast ß-glucan supplement. Both oat and yeast ßglucan have been shown to decrease low-density lipoprotein (LDL) cholesterol in
humans (Naumann et al., 2006; Nicolosi et al., 1999).

This parallel may indicate that

oat and yeast ß-glucan may be comparable in affecting different aspects of human
physiology.
Both psychological and physical stressors are shown to increase risk of upper
respiratory tract infections in mice and humans similarly (Davis et al., 1997; Nieman et
al., 2008; Hunzeker et al., 2004). Previous research has shown that mice participating in
a single bout of prolonged, vigorous exercise are at a higher risk for upper respiratory
tract infections than those who either underwent a short-term exercise or no exercise
(Davis et al., 1997). Oat ß-glucan has been shown to enhance immunity in mice and
prevent infection of the upper respiratory tract. Willment et al. (2001) found that the
human receptor of ß-glucan is both structurally and functionally similar to the mouse
receptor.
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Human research has found that oat ß-glucan offset increased upper respiratory
tract infection risk associated with exercise stress (Ceddia and Woods, 1999; Davis et al.,
2004). The similarities seen between oat and yeast ß-glucan in both murine and human
populations suggest that similar effects may be seen in other areas of physiology, such as
immune function. College-aged students generally suffer any combination of different
health affecting behaviors, which may cause a weakened immune system and increased
susceptibility to developing an URTI (Tsai and Li, 2004). To our knowledge no research
has succeeded in showing that a yeast ß-glucan supplement can improve symptoms of
upper respiratory tract infection in relatively healthy populations. Examining whether or
not ß-glucan can prevent these symptoms may have implications for maintaining immune
function in healthy, free-living populations. This research may also provide a better
understanding of how much each of the risk factors for URTI plays a role in preventing
and fighting URTI. The purpose of this study is to examine the effects of a yeast βglucan supplement on symptoms of upper respiratory tract infection in healthy, freeliving, college-aged males.
We hypothesized that the yeast β-glucan supplement would have no effect on
symptoms of upper respiratory tract infection in free-living, college-aged males.

METHODS
Subjects
There were 81 male, college-aged subjects in the study. Prior to participation, all
subjects completed an Institutional Review Board (IRB) approved informed consent form
(Tables 1-3).
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Descriptive Data
Descriptive Data was collected using four different methods. (1) A background
survey was completed by each subject which included age, gender, marital status, living
conditions, injuries which limit physical activity, dieting, caffeine intake, tobacco use,
and estimated consumption of foods with high amounts of ß-glucan; (2) a daily survey
completed by each subject during the twelve week study included twenty-four hour sleep
record in hours, twenty-four hour physical activity time in minutes, and twenty-four hour
stress level; and (3) an optional post study survey completed by the majority of subjects
included current height, current weight, estimated weight prior to study, how often and/or
easily subject accrues illness. Subjects were excluded from the study results if (1) they
were not within the 18-41 year age requirement throughout the study; (2) they did not
complete the background survey; or (3) they did not complete at least 75% (63) of the
daily surveys.
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Survey
Studies show that lab measurements to indicate upper respiratory tract infections
are not as accurate when compared to the individual’s perceived symptoms of upper
respiratory tract infection (Jackson et al., 1957; Barrett et al., 2002; Barrett et al., 2005;
Barrett et al., 2007). The Wisconsin Upper Respiratory Symptoms Survey (WURSS)
was developed as an evaluative illness specific quality-of-life instrument (Barrett et al.,
2008). The construct validity of the WURSS-44, a forty-four question version of the
survey, is supported by measures of reliability and responsiveness of subjects (Barrett et
al., 2005). This survey looks at thirty-two symptoms of upper respiratory tract infection,
ten functional quality-of-life items, one global illness severity item (How sick do you feel
today?), and one item assessing global change (Compared to yesterday how do you feel?)
(Barrett et al., 2005; Barrett et al., 2002). The survey allows subjects to score their
symptoms using a seven-point scale (0 = none, 1 = very mild, 3 = mile, 5 = moderate, 7 =
severe).

Data Collection

Each subject signed an Institutional Review Board (IRB) approved informed
consent form prior to participation in the study. Subjects were asked to take either a βglucan 250mg supplement or a placebo (rice flour) daily. Distribution of supplement and
placebo was done in a double-blind fashion. Along with taking the daily supplement or
placebo, each subject filled out an online survey (surveymonkey.com) which includes
questions about sleep, stress, physical activity, exposure to illness, includes the WURSS,
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and asks a final question about the subject’s belief of the cause of any symptoms (flu,
cold, allergies, etc.).

Statistical Procedures

Background descriptive data were analyzed using an independent t-test for age,
height (inches), pre-study weight (kg), post-study weight (kg), weight change (kg),
physical activity time (minutes spent daily participating in aerobic, resistance, and
organized sport activities, number of high school sports, caffeine intake (mg per week
from coffee, tea, or cola beverages), average sleep time (hours per night), average stress
level (0-10; not stressed-extremely stressed), number of allergies, average estimated βglucan intake (servings per week total and servings per week of oatmeal, cereal with oats,
other items with oats, barley, cereal with barley, other items with barley, mushrooms,
whole wheat bread, whole wheat pasta, other whole wheat foods, rye bread, other rye
foods) and will be expressed as Mean ± SD. For measures of daily sleep (hours per
night), stress (0-10; not stressed-extremely stressed), and physical activity (aerobic
exercise, resistance training, and organized sport; total physical activity minutes per day),
and average score was calculated for each variable for each subject. These measures
were analyzed using an independent t-test. Statistical significance was established at the
p < 0.05 level. These analyses were used to compare differences between the
experimental group (supplement) and the control group (placebo).
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RESULTS
Comparative baseline descriptive data are summarized in Table 1. There were no
significant differences between baseline descriptive data between groups. For measures
of pre-study and post-study weights there were no significant losses or gains for any
subjects, thus weight is reported as an average weight of the group calculated from the
average of each subject’s weight (kg) over the twelve weeks. Comparative subject intake
habits are summarized in Table 2. There were no significant differences between groups
with the exception of other food items consumed with oats (p = 0.02). Comparative
percent subject lifestyle characteristics are summarized in Table 3. There were no
significant differences between groups, with the exception of percentage of those who are
single (p = 0.01) and those who are partnered (p = .05).
Comparative data from the Wisconsin Upper Respiratory Symptom Survey are
summarized in Table 4. Yeast ß-glucan demonstrated no statistically significant effect
on the subjects for any of the variables (total number of days with symptoms, number of
URTI episodes, total number of days until the occurence of an URTI episode, the average
or maximum duration of an URTI episode, and the severity of URTI episodes).
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DISCUSSION
The purpose of this study was to examine the effects of a yeast β-glucan
supplement on symptoms of upper respiratory tract infection in healthy, free-living,
college-aged males.
The combination of prior research in mice and immunnosuppressed humans
suggests that β-glucan may have a beneficial effect on the immune system (Murphy et al.,
2008; Murphy et al., 2007; Davis et al., 2003). However, research also implies that sleep,
stress, nutritional behaviors, and physical activity has such diverse and profound effects
on the immune system that any benefits from a beta-glucan supplement seen in freeliving, healthy persons, are likely to be insignificant (Beisel, 1996; Dinges et al., 1995;
Cohen et al., 1991; Lac and Chamoux, 2003; Woods, 2005; Gleeson, 2007; Nieman,
2003; Nieman 2007). Previous research suggests that humans and mice have similar
immune systems and should see similar effects with a β-glucan supplement (Dinges et al.,
1995; Gleeson, 2007; Nieman, 2003; Nieman 2007). Along with this assertion is the
theory of an immune ceiling from beneficial effects from proper amounts of sleep, stress,
healthy nutritional behaviors, and healthy amounts of physical activity (Dinges et al.,
1995; Nieman, 2003; Nieman 2007). The non-significant findings of the present study
between the experimental and placebo groups agree with these theories.

Limitations
Although we aimed for socioeconomic diversity, our participants were volunteers
and may not have been representative of cold-sufferers. The data collected only applies
to healthy, free-living, college-aged males. Qualitative, self-reported survey data, may
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have been biased. The present research did not control for lifestyle habits, dietary habits,
or for any exposure to disease or infection.

CONCLUSION
The present research presents that a yeast β-glucan does not significantly decrease
occurrence of symptoms of URTI in humans. However, the population of healthy, freeliving, college-aged males tested in the present research may have an immune system
with a maximum level of prevention of URTI. Thus, any effects that a supplement may
have on the immune system may be masked by these levels. The limitations of the study
may prevent any effect that yeast β-glucan has on the immune functioning of the subjects.
It is recommended that future research on healthy, free-living subjects directs attention
toward statistically controlling for dietary, sleep, exposure, stress, and physical activity
habits.

REFERENCES
Barrett, B., K. Locken, R. Maberry, J. Schwamman, R. Brown, J. Bobula, and E.A. Stauffacher
(2002). “The Wisconsin upper respiratory symptom survey (WURSS).” Journal of
Family Practice 51: 249-257.
Barrett, B., R. Brown, and M. Mundt (2008). “Comparison of anchor-based and distributional
approaches in estimating important difference in common cold.” Quality of Life
Research 17:75-85.
Barrett, B., R. Brown, M. Mundt, N. Safdar, L. Dye, R. Maberry, J. Alt (2005). “The Wisconsin
upper respiratory symptom survey is responsive, reliable, and valid.” Journal of clinical
Epidemiology 58: 609-617.

77

Barrett, B., S. Enrizzi, P. Andreoli, S. Barlow, Z. Zhang (2007). “Clinical Significance of
Common Cold Treatment: Professionals’ Opinions.” Wisconsin Medical Journal
106(8): 473-480.
Biesel, W.R. (1996). Nutrition and immune function: overview. Journal of Nutrition 126:
2611S-2615S.
Brown, G.D. and S. Gordon (2003). “Fungal β-glucans and mammalian immunity.” Immunity
19: 311-315.
Brown, G.D. and S. Gordon (2005). “Immune recognition of fungal β-glucans.” Cellular
Microbiology 7(4): 471-479.
Ceddia, M.A. and J.A. Woods (1999). “Exercise suppresses macrophage antigen presentation.”
Journal of applied Physiology 87: 2253-2258.
Cohen, S., D.A.J. Tyrrell, and A.P. Smith (1991). “Psychological stress and susceptibility to the
common cold.” New England Journal of Medicine 325: 606-612.
Davis, J.M., E.A. Murphy, A.S. Brown, M.D. Charmichael, A. Ghaffar, and E.P. Mayer (2003).
“Effects of moderate exercise and oat β-glucan on innate immune function and
susceptibility to respiratory infection.” American Journal of Physiology – Regulatory,
Integrative, and Comparative Physiology 286: R366-R372.
Davis, J.M., E.A. Murphy, A.S. Brown, M.D. Charmichael, A. Ghaffar, and E.P. Mayer (2004).
“Effects of oat β-glucan on innate immunity and infection after exercise stress.”
Medicine and Science in Sports and Exercise 36(8): 1321-1327.
Davis, J.M., M.L/ Kohut, L.H. Colbert, D.A. Jackson, A. Ghaffar, and E.P. Mayer (1997).
“Exercise, alveolar macrophage function, and susceptibility to respiratory infection.”
Journal of Applied Physiology 83(5): 1461-1466.
Demir, G., H.O. Klein, N. Mandel-Molinas, N. Tuzuner (2007). “Beta glucan induces
proliferation and activation of monocytes in peripheral blood of patients with advanced
breast cancer.” International Immunology 7: 113-116.

78

Dinges, D.F., S.T. Douglas, S. Hamarman, L. Zaugg, and S. Kapoor (1995). Sleep deprivation
and human immune function. Advances in Neuroimmunology 5: 97-110.
Gleeson, M. (2007). “Immune function in sport and exercise.” Journal of Applied Physiology
103: 693-699.
Hunzeker, J., D.A. Padgett, P.A. Sheridan, F.S. Dhabhar, and J.F. Sheridan (2004).
“Modulation of natural killer cell activity by restraint stress during an influenza A/PR8
infection in mice.” Brain, Behavior, and Immunity 18:526-535.
Jackson, G.G., H.F. Dowling, I.G. Spiesman, and A.V. Boand (1957). “Transmission of the
common cold to volunteers under controlled conditions.” American Medical
Association Archives of Internal Medicine 101: 267-278.
Jenkins, D.J.A., et al. (2002). Soluble fiber intake at a dose approved by the US Food and Drug
Administration for cardiovascular disease assessed in a randomized controlled
crossover trial. American Journal of Clinical Nutrition 75: 834-839.
Lac, G. and A. Chamoux (2003). Elevated salivary cortisol levels as a result of sleep
deprivation in a shift worker. Occupational Medicine 53: 143-145.
Murphy, E.A., J.M. Davis, A.S. Brown, M.D. Charmichael, A. Ghaffar, and E.P. Mayer (2007).
“Oat β-glucan effects on neutrophil respiratory burst activity following exercise.”
Medicine and Science in Sports and Exercise 39(4): 639-644.
Murphy, E.A., J.M. Davis, et al. (2008). “Benefits of oat β-glucan on respiratory infection
following exercise stress: role of lung macrophages.” American Journal of Physiology
– Regulatory, Integrative, and Comparative Physiology 294: R1593-R1599.
Naumann, E., A.B. Van Rees, G. Onning, R. Oste, M. Wydra, and R.P. Mensink (2006). βglucan incorporated into a fruit drink effectively lowers serum LDL-cholesterol
concentrations. American Journal of Clinical Nutrtion 83: 601-605.

79

Nicolosi, R., S.J. Bell, B.R. Bistrian, I. Greenberg, R.A. Forse, and G.L. Blackburn (1999).
Plasma lipid changes after supplementation with ß-glucan fiber from yeast. American
Journal of Clinical Nutrition 70: 208-212.
Nieman, D.C. (2003). “Current Perspective on Exercise Immunology.” Current Sports
Medicine Reports 23: 239-242.
Nieman, D.C. (2007). “Marathon training and immune function.” Sports Medicine 37(4-5):
412-415.
Nieman, D.C., D.A. Henson, et al. (2008). “β-glucan, immune function, and upper respiratory
tract infections in athletes.” Medicine and Science in Sports and Exercise 40(8): 14631471.
Tsai, L., S. Li (2004). Sleep patterns in college students: gender and grade differences. Journal
of Psychosomatic Research 56: 231-237.
Vetvicka, V., B.P. Thornton, and G.D. Ross (1996). “Soluble β-glucan polysaccharide binding
to the lectin site of neutrophil or natural killer cell complement receptor type 3
(CD11b/CD18) generates a primed state of the receptor capable of mediating
cytotoxicity of iC3b-opsonized target cells.” Journal of Clinical Investigation 98(1):
50-61.
Willment, J.A., S. Gordon, and G.D. Brown (2001). “Characterization of the Human β-glucan
receptor and its alternatively spliced isoforms.” Journal of Biological Chemistry
276(47): 43818-4382.
Woods, J.A. (2005). Physical activity, exercise, and immune function. Brain, Behavior, and
Immunity 19: 369-370.
Yun, C.H., A. Estrada, A. Van Kessel, B. Park, B. Laarveld (2003). “β-glucan, extracted from
oat, enhances disease resistance against bacterial and parasitic infections.” FEMS
Immunology and Medical Microbiology 35: 67-75.

80

Appendix I

81

82

83

Appendix II

84

85

86

87

88

89

90

91

